September 12, 2013
Plandaí Moves Closer to Product Commercialization
Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.48 – Spec Buy) has made significant strides in recent months as it nears an inflection point which will migrate the Company from the development phase to the product commercialization phase. For example, Plandaí Biotechnology, through its wholly owned subsidiary, has completed its state-of-the-art production facility in Mpumalanga, South Africa, in the heart of its tea estate that sits on 7500 acres of land.
To ensure that the products are highly bioavailable, the unique processing and extraction system requires that the Company use only live plant material. Since the Company uses only live plant material, processing commences within an hour of the harvest.
There are a number of advantages to farming the extracts in South Africa, including the size and quality of the fertile land, economic benefits, and access to a farming teams with over 100 years of experience in managing farms in Southern Africa. The tea plant farmed on the property, Camellia Sinensis, is an evergreen shrub or tree and can grow to heights of 30 feet, but for proper cultivation purposes is pruned to heights of 2-5 feet only. In addition, this site farms a whole fruit basket of produce which it can potentially use in its creation of highly bioavailable extracts, including macadamia nuts, citrus, avocado, and artemesia, on top of its high profile 800+ hectares of tea.
Going forward, the farming team will soon fertilize and then allow the tea bushes to reestablish the high levels of polyphenols, before commercial production commences. The pre-production phase includes running test batches through the system and comparing those results to the original product profiles in order to guarantee the consistency of product quality prior to the commencement of full-scale production. Management anticipates that Phytofare™ Catechin Complex production will be ready by year-end with the exciting citrus-based Limonoid Glycoside Complex available in the summer of 2014. Thus, the turn of the year should be a major catalytic event for Plandaí Biotechnology and its shareholders.
For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com